Philadelphia chromosome‐positive acute lymphoblastic leukemia at first relapse in the era of tyrosine kinase inhibitors
Sign Up to like & getrecommendations! Published in 2019 at "American Journal of Hematology"
DOI: 10.1002/ajh.25648
Abstract: Despite the advances in the management of Philadelphia chromosome‐positive (Ph+) acute lymphoblastic leukemia (ALL) with the introduction of tyrosine kinase inhibitors (TKIs), relapses remain challenging. We reviewed clinical data from adult patients with Ph + ALL who… read more here.
Keywords: first relapse; positive acute; lymphoblastic leukemia; acute lymphoblastic ... See more keywords
Treatment and outcome of pediatric intracranial ependymoma after first relapse
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Neuro-Oncology"
DOI: 10.1007/s11060-022-03975-z
Abstract: Almost 50% of children with intracranial ependymoma experience disease relapse, and their outcomes are extremely poor. The aim of this study was to investigate optimal salvage treatment for pediatric intracranial ependymoma after the first relapse… read more here.
Keywords: pediatric intracranial; intracranial ependymoma; first relapse; treatment ... See more keywords
Bortezomib, cyclophosphamide, dexamethasone versus lenalidomide, cyclophosphamide, dexamethasone in multiple myeloma patients at first relapse
Sign Up to like & getrecommendations! Published in 2020 at "British Journal of Haematology"
DOI: 10.1111/bjh.16287
Abstract: Bortezomib‐ and lenalidomide‐containing regimens are well‐established therapies in multiple myeloma (MM). However, despite their extensive use, head‐to‐head comparisons have never been performed. Therefore, we compared bortezomib and lenalidomide in fixed‐duration therapies. In this open‐label, phase… read more here.
Keywords: first relapse; patients first; dexamethasone; cyclophosphamide dexamethasone ... See more keywords
Daratumumab, bortezomib and dexamethasone at first relapse for patients with multiple myeloma: A real‐world multicentre UK retrospective analysis
Sign Up to like & getrecommendations! Published in 2023 at "British Journal of Haematology"
DOI: 10.1111/bjh.18703
Abstract: Daratumumab, bortezomib and dexamethasone (DVd) is approved for patients with relapsed multiple myeloma following the CASTOR phase 3 clinical trial. This retrospective multicentre analysis assesses the overall response rate (ORR) and progression‐free survival (PFS) in… read more here.
Keywords: bortezomib; daratumumab bortezomib; multiple myeloma; first relapse ... See more keywords
Induction Toxicities Are More Frequent in Young Adults Compared to Children Treated on the Children's Oncology Group (COG) First Relapse B-Lymphoblastic Leukemia Clinical Trial AALL1331
Sign Up to like & getrecommendations! Published in 2018 at "Blood"
DOI: 10.1182/blood-2018-99-112269
Abstract: Background COG AALL1331 randomizes first relapse B-lymphoblastic leukemia (B-ALL) patients ages 1-30 years (yrs) to standard chemotherapy +/- blinatumomab after a common Induction (Block 1) based on the mitoxantrone arm of UKR3 ALL (Parker et… read more here.
Keywords: first relapse; relapse; oncology; relapse lymphoblastic ... See more keywords
Treatment Efficacy in Relapsed/Refractory Multiple Myeloma: Outcomes Based on Racial Disparity
Sign Up to like & getrecommendations! Published in 2018 at "Blood"
DOI: 10.1182/blood-2018-99-119181
Abstract: Introduction: There have been major advances in the diagnosis, staging, risk-stratification, and management of multiple myeloma (MM). Novel triplet regimens containing drugs such as Carfilzomib, Elotuzumab, Daratumumab, or Ixazomib have improved the median progression-free survival… read more here.
Keywords: first relapse; treatment; multiple myeloma; progression ... See more keywords
Depth of Pre-Treatment Immunoparesis Is an Important Prognostic Factor for Survival in Relapsed Multiple Myeloma
Sign Up to like & getrecommendations! Published in 2019 at "Blood"
DOI: 10.1182/blood-2019-123861
Abstract: Background: Suppression of uninvolved immunoglobulins [Ig], or immunoparesis, is associated with an inferior progression-free survival [PFS] and overall survival [OS] in patients with newly diagnosed multiple myeloma [MM]. However, immunoparesis in relapsed MM can be… read more here.
Keywords: first relapse; quantitative immunoparesis; immunoparesis; therapy ... See more keywords
Prospective phase II trial in patients with first relapse of high-grade astrocytoma using TVB-2640 in combination with bevacizumab versus bevacizumab alone.
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2019.37.15_suppl.2064
Abstract: 2064 Background: Recurrent glioblastoma (rGBM) following chemoradiation is associated with a poor prognosis. While bevacizumab is the most common salvage therapy, responses remain brief and without an associated survival benefit. Resistance may involve overexpression of… read more here.
Keywords: bevacizumab; combination; treatment; tvb 2640 ... See more keywords
Mantle cell lymphoma patients in first relapse: we pretty much know what to do
Sign Up to like & getrecommendations! Published in 2021 at "Oncotarget"
DOI: 10.18632/oncotarget.27980
Abstract: Treatment of relapsed mantle cell lymphoma (MCL) patients is challenging. Disease behavior has typically been described to be largely heterogeneous [1]. The MANTLE-FIRST study, the first patient-level analysis of outcomes of relapsed-refractory (r/r) MCL after… read more here.
Keywords: first relapse; treatment; cell lymphoma; mantle cell ... See more keywords
Natural History and Prognostic Factors at First Relapse in Multiple Myeloma
Sign Up to like & getrecommendations! Published in 2020 at "Cancers"
DOI: 10.3390/cancers12071759
Abstract: The prognosis of multiple myeloma has considerably improved due to the introduction of novel agents in the upfront setting. However, the great majority of patients ultimately relapse, and choosing a salvage treatment at first relapse… read more here.
Keywords: multiple myeloma; natural history; first relapsed; first relapse ... See more keywords